Thermo Fisher insider trades under 10b5-1 plan: matched buys and sells
Rhea-AI Filing Summary
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported multiple transactions on Form 4. On 08/19/2025 and 08/20/2025 the filing shows purchases of common stock (totaling 496 shares) at $253.99 and contemporaneous sales of common stock (totaling 496 shares) at a weighted-average price near $500.17. Following the reported trades, the filing lists total beneficial ownership of common stock at approximately 115,173.623 shares (direct) plus several indirect holdings: 11,300, 14,608, and 5,000 shares via trusts or entities. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted April 28, 2025, and includes option-related entries showing acquisition of stock options with underlying shares of 201 and 295 that vest/exercisable per earlier vesting dates.
Positive
- Trades executed under a Rule 10b5-1 trading plan, indicating pre-approved, documented framework for insider trades
- Timely Form 4 filing signed by attorney-in-fact, showing compliance with Section 16 reporting
Negative
- Insider sold 496 shares at a weighted-average near $500.17, representing realized dispositions that reduce direct holdings
- Large price spread between purchases at $253.99 and sales near $500.17 noted in the record (no explanation provided in filing)
Insights
Insider executed matched purchases and sales under a 10b5-1 plan, materially moving shares at two distinct price levels.
The Form 4 shows Marc N. Casper both acquired and sold 496 common shares across 08/19/2025–08/20/2025, with purchases recorded at $253.99 and sales executed at a weighted-average near $500.17. The matched volumes and the stated 10b5-1 plan adoption indicate pre-approved, rule-compliant trading rather than opportunistic timing. Reported direct beneficial ownership remains about 115.2k shares with additional indirect holdings through trusts and entities. For valuation context, the spread between acquisition and sale prices is large; however, the filing does not state aggregate dollar amounts or motives beyond plan execution.
Transactions were performed under an explicit Rule 10b5-1 plan, which supports procedural compliance and reduces signaling risk.
The disclosure clearly identifies the trades as effected pursuant to a 10b5-1 trading plan adopted April 28, 2025, and the Form 4 is signed by an attorney-in-fact. The filing also discloses indirect holdings via trusts and an entity, with explicit disclaimers of beneficial ownership to the extent noted. From a governance perspective, timely reporting and the plan reference are positive controls; the filing contains no statements of deviation from plan terms or exceptions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 295 | $0.00 | -- |
| Exercise | Common Stock | 295 | $253.99 | $75K |
| Sale | Common Stock | 200 | $500.00 | $100K |
| Sale | Common Stock | 95 | $500.13 | $48K |
| Exercise | Stock Option (Right to Buy) | 201 | $0.00 | -- |
| Exercise | Common Stock | 201 | $253.99 | $51K |
| Sale | Common Stock | 201 | $500.1671 | $101K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.002 to $500.317, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. The option vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
